论文部分内容阅读
目的:探究肺部肿瘤低剂量CT引导下射频消融联合化疗的临床有效性。方法:收集2015年6月~2016年12月在我院接受治疗的88例肺部肿瘤患者作为研究对象,按随机原则分为低剂量组与正常剂量组,低剂量组采用低剂量CT引导下射频消融联合化疗,正常剂量组采用正常剂量CT引导下射频消融联合化疗,比较两组的CT权重质量指数、计量长度乘积。结果:正常剂量组CT权重质量指数(17.78)与低剂量组CT权重质量指数(17.89)差异小,无统计学意义(P>0.05);正常剂量组计量长度乘积(6549.72±4728.65%)与低剂量组计量长度乘积(2479.35±1126.98%)比较,发现P<0.05,具有统计学意义。结论:低剂量CT引导下射频消融联合化疗治疗肺部肿瘤,疗效可靠,值得临床推广使用。
Objective: To investigate the clinical efficacy of radiofrequency catheter ablation combined with chemotherapy guided by low-dose CT in lung cancer. Methods: Totally 88 patients with lung cancer who were treated in our hospital from June 2015 to December 2016 were selected as the research object. According to the randomized principle, the patients were divided into low dose group and normal dose group. Low dose CT group Radiofrequency ablation combined with chemotherapy, normal dose group under the guidance of normal dose CT radiofrequency catheter ablation combined with chemotherapy, compared the two groups of CT weight quality index, measurement length product. Results: The CT weight index (17.78) and CT weight index (17.89) in the normal dose group were significantly lower than those in the low dose group (P <0.05). The product of the measurement length of normal dose group (6549.72 ± 4728.65% Dose group measurement length product (2479.35 ± 1126.98%), found that P <0.05, with statistical significance. Conclusion: Low-dose CT-guided radiofrequency catheter ablation combined with chemotherapy for lung tumors is reliable and worthy of clinical application.